SavedAdd your journal

Journals / Journal of Clinical and Analytical Medicine / 2015 / Cilt: 6 - Sayı: 2

Küçük Hücreli Dışı Akciğer Kanserli Hastalarda Erlotinibin Klinik Etkinliğinin Retrospektif Analizi

Retrospective Analysis of Clinical Efficacy of Erlotinib in Patients with Non-Small Cell Lung Cancer

Adem DELİGÖNÜL
Özkan KANAT
Aylin AYYILDIZ
Vildan GÜRSOY
Güven ÖZKAYA
Pages
212–215
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median progression-free survival was 242 days (95% CI51-224), and the median overall survival (OS) was 377 days (95% CI 291- 462).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In this study, we aimed to evaluate the efficacy and safety of erlotinib assecond-, third-, and fourth-line treatment for Turkish patients with advancednon-small cell lung cancer (NSCLC).
📊
Key Findings & Data:Material and Method: Thirty-nine patients with advanced, previously treated NSCLC who received 150 mg of erlotinib once daily orally until disease progression or intolerable toxicity wereretrospectively analyzed.
💡
Conclusion & Impact:The median progression-free survival was 242 days (95% CI51-224), and the median overall survival (OS) was 377 days (95% CI 291- 462).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: In this study, we aimed to evaluate the efficacy and safety of erlotinib assecond-, third-, and fourth-line treatment for Turkish patients with advancednon-small cell lung cancer (NSCLC). Material and Method: Thirty-nine patients with advanced, previously treated NSCLC who received 150 mg of erlotinib once daily orally until disease progression or intolerable toxicity wereretrospectively analyzed. Results: We observed no complete response, partialresponses were observed in 7 (17.9%) patients, and 16 (41%) patients hadstable disease. The median progression-free survival was 242 days (95% CI51-224), and the median overall survival (OS) was 377 days (95% CI 291- 462). The median OS of females was significantly better than male patients(470 vs. 271 days, p=0.046). The treatment was generally well tolerated. Themost common side effect was skin rash (41%). Discussion: Erlotinib was safeand effective in treating Turkish patients with advanced NSCLC who hadbeen previously treated with the standard chemotherapy.

Özet

Amaç: Bu çalışmada, ileri evre küçük hücreli dışı akciğer kanseri (KHDAK) olanTürk hastalarda, ikinci, üçüncü ve dördüncü seçim olarak uygulanan erlotinibin etkinlik ve güvenilirliğinin değerlendirilmesi amaçlandı. Gereç ve Yöntem:Daha önce tedavi görmüş, ileri evre KHDAK olan ve hastalık progresyonuna veya tolere edilemeyen bir yan etki oluşana kadar, oral yoldan günde 150mg erlotinib alan 39 hasta retrospektif olarak analiz edildi. Bulgular: Tam yanıt gözlenmezken, 7 (%17.9) hastada kısmi yanıt ve 16 (%41) hastada stabil hastalık tespit edildi. Ortalama progresyonsuz sağkalım süresi 242 gün(%95 CI 51-224) ve ortalama genel sağkalım süresi ise 377 gündü (%95 CI291-462). Genel sağkalım süresi kadınlarda erkeklere oranla anlamlı düzeydedaha uzundu (470 vs. 271 gün, p=0.046). Tedavi genel olarak iyi tolere edildi. En sık gözlenen yan etki cilt döküntüsü idi (%41). Tartışma: Erlotinib dahaönce standart kemoterapi almış ileri evre KHDAK olan Türk hastaların tedavisinde güvelinilir ve etkili bulundu.

🔖

Cite This Article

DELİGÖNÜL, A., KANAT, Ö., AYYILDIZ, A., GÜRSOY, V., ÖZKAYA, G. (2022). Küçük Hücreli Dışı Akciğer Kanserli Hastalarda Erlotinibin Klinik Etkinliğinin Retrospektif Analizi. Journal of Clinical and Analytical Medicine, Cilt: 6 - Sayı: 2, 212–215. https://ajindex.com/articles/553917

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Cufer T, Ovcaricek T, O’Brien ME. Systemic therapy of advanced non- small cell lung cancer: major-developments of the last 5-years. Eur J Cancer 2013;49(6):1216-25
  2. Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK. Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010;5(2):260-74
  3. Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther 2013;13(6):745-58
  4. Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation- positive patients. Cancer Treat Rev 2013;39(8):839-50
  5. Bayraktar S, Rocha-Lima CM. Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World J Clin Oncol 2013;4(2):29-42
  6. D’Arcangelo M, Cappuzzo F. Erlotinib in the first-line treatment of non-small-cell lung cancer Expert Rev Anticancer Ther 2013;13(5):523-33
  7. Majem M, Pallares C. An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents Clin Transl Oncol 2013;15(5):343-57
  8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
  9. Farhat FS, Houhou W. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther Adv Med Oncol 2013;5(4):249-70
  10. Gridelli C, Maione P, Bareschino MA, Schettino C, Sacco PC, Ambrosio R et al. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res 2010;30(4):1301-10
  11. Karaca H, GeredeliC, Kaplan Ma, DemirciU, Alıcı S, Artac M, et al. Efficacy and safety of erlotinib in previously treated advanced non-small cell lung cancer. UHOD 2013;23(1):1-6
  12. Yamada K, Takayama K, Kawakami S, Saruwatari K, Morinaga R, Harada T et al. Phase II trial of erlotinib for Japanese patients with previously treated non- small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK080). Jpn J Clin Oncol 2013;43(6):629-35.